Compare TMCI & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMCI | MCRB |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.4M | 139.7M |
| IPO Year | 2021 | 2015 |
| Metric | TMCI | MCRB |
|---|---|---|
| Price | $1.38 | $9.35 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 3 |
| Target Price | $4.77 | ★ $14.33 |
| AVG Volume (30 Days) | ★ 852.4K | 48.4K |
| Earning Date | 05-19-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | ★ $212,690,000.00 | $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.65 | N/A |
| P/E Ratio | ★ N/A | $14.72 |
| Revenue Growth | ★ 1.59 | N/A |
| 52 Week Low | $1.31 | $0.36 |
| 52 Week High | $8.84 | $29.98 |
| Indicator | TMCI | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 34.96 | 40.94 |
| Support Level | $1.31 | $6.99 |
| Resistance Level | $3.06 | $9.60 |
| Average True Range (ATR) | 0.15 | 0.51 |
| MACD | 0.01 | 0.24 |
| Stochastic Oscillator | 9.55 | 43.33 |
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.